AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7564037 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of buprenorphine (intermittent injection before awakening from anesthesia)
Number of subjects: 46
Study 7564037 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural injection of buprenorphine (continuous injection)
Number of subjects: 46
Study 2117332 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 35 micrograms (n = 51)
Number of subjects: 207
Study 2117332 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil 70 micrograms (n = 53)
Number of subjects: 207
Study 2117332 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 103)
Number of subjects: 207
Study 6113683 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg l-hyoscyamine
Number of subjects: 8
Study 6113683 — intervention group
Group type: COMPARATOR
Intervention: 50 mg trimipramine
Number of subjects: 8
Study 6113683 — intervention group
Group type: COMPARATOR
Intervention: 150 mg ranitidine
Number of subjects: 8
Study 6113683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31805989 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06650833 IR 30 mg
Number of subjects: 0
Study 31805989 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06650833 MR 100 mg
Number of subjects: 0
Study 31805989 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06650833 IR 100 mg
Number of subjects: 0
Study 31805989 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06650833 IR <750 mg and MR 300 mg
Number of subjects: 0
Study 31805989 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06650833 IR ≥250 mg and MR 300 mg
Number of subjects: 0
Study 31805989 — intervention group
Group type: COMPARATOR
Intervention: PF-06650833 IR 25 to 750 mg, IR 1000 mg four times per day, IR 330 mg three times per day, MR 300 mg QD
Number of subjects: 0
Study 31805989 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06650833
Number of subjects: 0
Study 27437568 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TEAS combined with intraoperative TEAS (group TTS)
Number of subjects: 380
Study 27437568 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TEAS combined with postoperative TEAS (group TST)
Number of subjects: 380
Study 27437568 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS (group SSS)
Number of subjects: 380
Study 27437568 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative TEAS (group TSS)
Number of subjects: 380
Study 26370288 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing Aid Tool (WAT)
Number of subjects: 41
Study 26370288 — intervention group
Group type: COMPARATOR
Intervention: Control (no reminders)
Number of subjects: 41
Study 24041301 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligence measure
Number of subjects: 0
Study 24041301 — intervention group
Group type: COMPARATOR
Intervention: Conscious strategies engagement
Number of subjects: 0
Study 24041301 — intervention group
Group type: COMPARATOR
Intervention: Conscious influences removal
Number of subjects: 0
Study 21435854 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort® Turbuhaler® maintenance and reliever therapy (Symbicort SMART®), 160/4.5 μg 1 × 2
Number of subjects: 8053
Study 21435854 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort® Turbuhaler® maintenance and reliever therapy (Symbicort SMART®), 2 × 2
Number of subjects: 8053
Study 21435854 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (1 × 2)
Number of subjects: 8053
Study 21435854 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (2 × 2)
Number of subjects: 8053
Study 21435854 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol maintenance and reliever therapy
Number of subjects: 8053
Study 21435854 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients
Number of subjects: 8053
Study 19218880 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 609
Study 19218880 — intervention group
Group type: COMPARATOR
Intervention: Side position
Number of subjects: 609
Study 17940604 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 405
Study 17940604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 15503754 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-centered instruction
Number of subjects: 40
Study 15503754 — intervention group
Group type: COMPARATOR
Intervention: Student-centered instruction
Number of subjects: 40
Study 11324212 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostheses connected to ball abutments after a maximum of 3 weeks
Number of subjects: 21
Study 11324212 — intervention group
Group type: COMPARATOR
Intervention: Implants loaded with an overdenture connected with ball abutments after 3 months (control group)
Number of subjects: 21
Study 9270507 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.05%
Number of subjects: 298
Study 9270507 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.01%
Number of subjects: 298
Study 8288696 — intervention group
Group type: EXPERIMENTAL
Intervention: Decapeptyl (3.75 mg, im, every 28 days for 6 months) with estrogen (conjugated equine estrogens, 0.625 mg for 21 days and medroxyprogesterone acetate, 10 mg for 10 days)
Number of subjects: 22
Study 8288696 — intervention group
Group type: COMPARATOR
Intervention: Decapeptyl (3.75 mg, im, every 28 days for 6 months) alone
Number of subjects: 22
Study 3293255 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with small doses of prednisolone (5 mg) and chlorambucil (4 mg)
Number of subjects: 80
Study 3293255 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate and ibuprofen
Number of subjects: 80
Study 3293255 — intervention group
Group type: COMPARATOR
Intervention: Control group (local therapy of the parotid glands)
Number of subjects: 80
Study 30685440 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL triglycerides
Number of subjects: 3140
Study 30685440 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hepatic lipase activity
Number of subjects: 3140
Study 28561554 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk with 0.185 mg F
Number of subjects: 9
Study 28561554 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated milk with 0.375 mg F
Number of subjects: 9
Study 28561554 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no fluoride added milk) with non-fluoride toothpaste
Number of subjects: 9
Study 28561554 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (1,000 ppm)
Number of subjects: 9
Study 26780018 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg, twice daily starting on the day of surgery until the seventh day post-operatively or discharge
Number of subjects: 252
Study 26780018 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical patients)
Number of subjects: 252
Study 26780018 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib treatment
Number of subjects: 252
Study 23377833 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise only (EX)
Number of subjects: 11
Study 23377833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI) after exercise
Number of subjects: 11
Study 23377833 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) - no exercise
Number of subjects: 11
Study 23377833 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 11
Study 23377833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 11
Study 21943384 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated TB DOTS plus smoking cessation intervention (SCIDOTS group)
Number of subjects: 120
Study 21943384 — intervention group
Group type: COMPARATOR
Intervention: Conventional TB DOTS alone (DOTS group)
Number of subjects: 120
Study 19064841 — intervention group
Group type: COMPARATOR
Intervention: Atropine eyedrops (weekend use)
Number of subjects: 193
Study 19064841 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching of the sound eye (2 hours per day)
Number of subjects: 193
Study 16945213 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 0
Study 14578226 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic plus resistance training (Ae+RT)
Number of subjects: 28
Study 14578226 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic only training (Ae only)
Number of subjects: 28
Study 14578226 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study 10749783 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (lowest dose)
Number of subjects: 0
Study 10749783 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (highest dose)
Number of subjects: 0
Study 10749783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8703455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 14
Study 8703455 — intervention group
Group type: COMPARATOR
Intervention: Obstructive sleep apnea syndrome
Number of subjects: 14
Study 8703455 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass procedure
Number of subjects: 14
Study 1305043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain (2.5 to 25 mg per injection, intramuscularly or intravenously, every 1-5 days)
Number of subjects: 70
Study 1305043 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain (various dosing schedules and intervals)
Number of subjects: 70
Study 3977491 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 micrograms of heat-inactivated hepatitis B vaccine
Number of subjects: 227
Study 3977491 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 micrograms of heat-inactivated hepatitis B vaccine
Number of subjects: 227
Study 29884682 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA supplementation
Number of subjects: 420
Study 29884682 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 420
Study 26708675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling plus 30% inhaled xenon for 24 h started immediately after randomisation.
Number of subjects: 92
Study 26708675 — intervention group
Group type: COMPARATOR
Intervention: Cooling to a rectal temperature of 33·5°C for 72 h (standard treatment).
Number of subjects: 92
Study 24866594 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep condition
Number of subjects: 40
Study 24866594 — intervention group
Group type: COMPARATOR
Intervention: No-sleep condition
Number of subjects: 40
Study 23197572 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (a phosphodiesterase 5A inhibitor), single dose
Number of subjects: 0
Study 23197572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21542450 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help workbook
Number of subjects: 49
Study 21542450 — intervention group
Group type: COMPARATOR
Intervention: Information booklet (control)
Number of subjects: 49
Study 18091705 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial magnetic resonance lymphography (MRL) using subcutaneous gadobutrol (5 mL: 4.5 mL Gadobutrol + 0.5 mL lidocaine hydrochloride)
Number of subjects: 6
Study 18091705 — intervention group
Group type: COMPARATOR
Intervention: X-ray direct lymphography (lipiodol administered after 7 days in 3 patients)
Number of subjects: 6
Study 16298064 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 130
Study 16298064 — intervention group
Group type: EXPERIMENTAL
Intervention: First-degree relatives of children with headache
Number of subjects: 130
Study 16298064 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 130
Study 16298064 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without primary headache)
Number of subjects: 130
Study 12077007 — intervention group
Group type: EXPERIMENTAL
Intervention: British Sign Language (BSL) processing in congenitally deaf native users
Number of subjects: 18
Study 12077007 — intervention group
Group type: COMPARATOR
Intervention: Audio-visual English processing in hearing non-signers
Number of subjects: 18
Study 12077007 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of BSL and audio-visual English
Number of subjects: 18
Study 12077007 — intervention group
Group type: EXPERIMENTAL
Intervention: BSL in deaf signers
Number of subjects: 18
Study 12077007 — intervention group
Group type: COMPARATOR
Intervention: Audio-visual English in hearing subjects
Number of subjects: 18
Study 9462315 — intervention group
Group type: EXPERIMENTAL
Intervention: Community multidisciplinary teams
Number of subjects: 155
Study 9462315 — intervention group
Group type: COMPARATOR
Intervention: Hospital based care programmes
Number of subjects: 155
Study 7630032 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation education program at branch A
Number of subjects: 2
Study 7630032 — intervention group
Group type: COMPARATOR
Intervention: No smoking cessation education at branch B
Number of subjects: 2
Study 2799034 — intervention group
Group type: EXPERIMENTAL
Intervention: Creon (7 capsules, 2.1 g pancreatin, 70,000 UFIP lipase)
Number of subjects: 12
Study 2799034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pankreon 700 (17 tablets, 11.9 g pancreatin, 476,000 UFIP lipase)
Number of subjects: 12
Study 2799034 — intervention group
Group type: COMPARATOR
Intervention: Control (first week without treatment)
Number of subjects: 12
Study 31609974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentor Mother (MM) programme
Number of subjects: 2304
Study 31609974 — intervention group
Group type: COMPARATOR
Intervention: Standard PMTCT services without MM intervention
Number of subjects: 2304
Study 29178761 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/ProRoot mineral trioxide aggregate (MTA)
Number of subjects: 412
Study 29178761 — intervention group
Group type: EXPERIMENTAL
Intervention: FP/calcium enriched mixture (CEM)
Number of subjects: 412
Study 25580606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-channel portable monitor (PM)
Number of subjects: 104
Study 25580606 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-channel portable monitor (PM) in simultaneous laboratory comparison
Number of subjects: 104
Study 25580606 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual PM data review
Number of subjects: 104
Study 23427838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic tape intervention (audio recording of a hypnotic induction with suggestions for progressive relaxation, imagery, and anchoring) used for 2 weeks
Number of subjects: 35
Study 23427838 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 35
Study 23427838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic tape intervention
Number of subjects: 35
Study 21358373 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coached telephone intervention
Number of subjects: 102
Study 21358373 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 102
Study 19082662 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication without division of short gastric vessels (group 1, n = 19)
Number of subjects: 41
Study 19082662 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication with division of short gastric vessels (group 2, n = 22)
Number of subjects: 41
Study 16395320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet
Number of subjects: 65
Study 16395320 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 65
Study 15054404 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg/d isoflavone supplement for 3 months
Number of subjects: 15
Study 15054404 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented diets
Number of subjects: 15
Study 10828806 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours of nasal packing
Number of subjects: 104
Study 10828806 — intervention group
Group type: COMPARATOR
Intervention: 48 hours of nasal packing
Number of subjects: 104
Study 9104618 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal administration of an IgA enriched preparation
Number of subjects: 36
Study 9104618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8478668 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 160 mg/d
Number of subjects: 342
Study 8478668 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 480 mg/d
Number of subjects: 342
Study 8478668 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 800 mg/d
Number of subjects: 342
Study 8478668 — intervention group
Group type: EXPERIMENTAL
Intervention: Megestrol acetate 1280 mg/d
Number of subjects: 342
Study 3532099 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline
Number of subjects: 21
Study 3532099 — intervention group
Group type: COMPARATOR
Intervention: pirlindol
Number of subjects: 21
Study 3532099 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 21
Study 31580044 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy device (group C)
Number of subjects: 71
Study 31580044 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic glue (group B)
Number of subjects: 71
Study 31580044 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure (group A)
Number of subjects: 71
Study 30056414 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror Therapy (MT)
Number of subjects: 30
Study 26272330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg QD × 5 days)
Number of subjects: 34
Study 26272330 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg QD × 5 days)
Number of subjects: 34
Study 26272330 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (40-g single dose)
Number of subjects: 34
Study 24763156 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy intervention (6-week program, twice weekly group classes and once weekly home practice)
Number of subjects: 19
Study 24763156 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy intervention
Number of subjects: 19
Study 24763156 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 19
Study 22667695 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS group
Number of subjects: 150
Study 22667695 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional group
Number of subjects: 150
Study 22667695 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 150
Study 20185596 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (40 mg every 28 days)
Number of subjects: 12
Study 20185596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 20185596 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 12
Study 19022134 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction and mandibulomaxillary fixation (CRMMF)
Number of subjects: 66
Study 19022134 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 66
Study 15750149 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe A (scintillator with bismuth germanate crystal)
Number of subjects: 200
Study 15750149 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe B (semiconductor with cadmium telluride crystal)
Number of subjects: 200
Study 15750149 — intervention group
Group type: EXPERIMENTAL
Intervention: Probe C (semiconductor with cadmium zinc telluride crystal)
Number of subjects: 200
Study 15750149 — intervention group
Group type: COMPARATOR
Intervention: All probes
Number of subjects: 200
Study 12198052 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI) of propofol (plasma target concentration, 2.5-3.5 micro g/mL; n = 20)
Number of subjects: 40
Study 12198052 — intervention group
Group type: COMPARATOR
Intervention: Manually-Controlled Infusion (MCI) of propofol (3.0-4.0 mg.kg(‐1).h(‐1); n = 20)
Number of subjects: 40
Study 12198052 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to extubation (TCI: 13.7 +/- 5.3 min; MCI: 12.3 +/- 3.5 min)
Number of subjects: 40
Study 12198052 — intervention group
Group type: COMPARATOR
Intervention: Costs of anesthesia (TCI: 39.73 US dollars; MCI: 34.83 US dollars)
Number of subjects: 40
Study 12198052 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS measurements at various time points (T1 to T6)
Number of subjects: 40
Study 10670292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegasus Trinova (dynamic integrated mattress and seat cushion system)
Number of subjects: 0
Study 10670292 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory measures of interface pressure
Number of subjects: 0
Study 7489931 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy + omeprazole (20 mg twice daily)
Number of subjects: 336
Study 7489931 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy + famotidine (40 mg at night)
Number of subjects: 336
Study 2031196 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonidamine, 350 mg/m2 orally daily (arm A)
Number of subjects: 60
Study 2031196 — intervention group
Group type: COMPARATOR
Intervention: High dose tamoxifen, 150 mg/m2 orally daily for 6 months, then 50 mg/m2 until tumor progression (arm B)
Number of subjects: 60
Study 16435471 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (320 mg/day)
Number of subjects: 40
Study 16435471 — intervention group
Group type: COMPARATOR
Intervention: cimetidine (800 mg/day)
Number of subjects: 40
Study 16435471 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine (150 mg twice daily)
Number of subjects: 40
Study 16435471 — intervention group
Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 40
Study 31022886 — intervention group
Group type: EXPERIMENTAL
Intervention: Organizational intervention targeting work organization and environment
Number of subjects: 0
Study 31022886 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific intervention details provided)
Number of subjects: 0
Study 28167545 — intervention group
Group type: COMPARATOR
Intervention: MRX-I single ascending doses under fasting or fed condition
Number of subjects: 66
Study 28167545 — intervention group
Group type: COMPARATOR
Intervention: MRX-I 800 mg every 12 hours for 14 days
Number of subjects: 66